WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Frequently asked questions
What sector does WuXi XDC Cayman Inc (2268) operate in?
WuXi XDC Cayman Inc belongs to the Materials sector and operates in the Diagnostics & Research industry.
What is WuXi XDC Cayman Inc (2268) current stock price?
As of the latest data, WuXi XDC Cayman Inc stock price is HK$81.00, with a previous close of HK$81.00.
What is WuXi XDC Cayman Inc (2268) current market capitalization?
WuXi XDC Cayman Inc market cap is approximately 102.58 billion.
What is WuXi XDC Cayman Inc (2268) EBITDA?
WuXi XDC Cayman Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.18 billion.
Does WuXi XDC Cayman Inc (2268) pay dividends?
No. WuXi XDC Cayman Inc does not pay a dividend.
When is WuXi XDC Cayman Inc (2268) next earnings report?
WuXi XDC Cayman Inc is expected to release its next earnings report on December 31, 2026.
What is WuXi XDC Cayman Inc (2268) beta (volatility) score?
WuXi XDC Cayman Inc has a beta of -0.764, indicating lower volatility than the overall market.
